DC1s shield Tpex cells to bolster PD-1 blockade

David G Brooks; Pamela S Ohashi

doi:10.1016/j.immuni.2022.03.017

DC1s shield Tpex cells to bolster PD-1 blockade

Immunity. 2022 Apr 12;55(4):577-579. doi: 10.1016/j.immuni.2022.03.017.

Authors

David G Brooks¹, Pamela S Ohashi²

Affiliations

¹ Princess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada. Electronic address: dbrooks@uhnresearch.ca.
² Princess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada. Electronic address: pam.ohashi@uhnresearch.ca.

PMID: 35417669
DOI: 10.1016/j.immuni.2022.03.017

Abstract

Responsiveness to PD-1 blockade depends on a cell subset known as Tpex cells, but how these cells are sustained is less understood. In this issue of Immunity, Dähling et al. show how dendritic cells form a niche for Tpex preservation.

Publication types

Comment

MeSH terms

Programmed Cell Death 1 Receptor*

Substances

Programmed Cell Death 1 Receptor